Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: CMP-001
Drug: Pembrolizumab

First Posted Date: 2020-11-18

Last Posted Date: 2024-10-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04633278

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Southern California: Norris Oncology/Hematology - Newport Beach, Newport Beach, California, United States
🇺🇸
University of California - San Diego, La Jolla, California, United States

and more 16 locations

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: REGN7075
Drug: cemiplimab
Drug: Platinum-based doublet chemotherapy

First Posted Date: 2020-11-12

Last Posted Date: 2024-10-21

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 769

Registration Number: NCT04626635

Locations: 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
University of Florida Health, Gainesville, Florida, United States
🇹🇷
Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

and more 33 locations

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Conditions: COVID-19

First Posted Date: 2020-11-05

Last Posted Date: 2023-10-03

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT04617535

Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

Phase 1

Terminated

Conditions: Healthy Volunteer

Interventions: Drug: REGN6490
Drug: Placebo

First Posted Date: 2020-11-04

Last Posted Date: 2021-11-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT04616079

Locations: 🇧🇪
Regeneron Study Site, Ghent, Belgium

Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

Phase 1

Terminated

Conditions: Healthy Volunteer

Interventions: Drug: REGN6490
Drug: Placebo

First Posted Date: 2020-11-04

Last Posted Date: 2021-11-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT04616105

Locations: 🇺🇸
Regeneron Study Site, Glendale, California, United States

T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Not Applicable

Completed

Conditions: Celiac Disease

Interventions: Dietary Supplement: Gluten Powder

First Posted Date: 2020-11-04

Last Posted Date: 2024-06-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT04614571

Locations: 🇺🇸
Celiac Research Centre Mass General Hospital, Boston, Massachusetts, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pozelimab
Drug: Cemdisiran

First Posted Date: 2020-10-26

Last Posted Date: 2021-11-12

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT04601844

Locations: 🇧🇪
Regeneron Research Site, Antwerp, Belgium

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Phase 1

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Endometrial Cancer

Interventions: Drug: REGN5668
Drug: REGN4018
Drug: Cemiplimab
Drug: Sarilumab

First Posted Date: 2020-10-19

Last Posted Date: 2024-12-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 612

Registration Number: NCT04590326

Locations: 🇪🇸
Ciudad Universitaria, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM, Madrid, Spain
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 18 locations